Bio Vitos Pharma AB (publ) (STO:BIOVIT)

Market Cap	4.73M
Revenue (ttm)	410.63K
Net Income (ttm)	-19.86M
Shares Out	39.40M
EPS (ttm)	-0.50
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,153,263
Average Volume	1,388,786
Open	0.1250
Previous Close	0.1250
Day's Range	0.0900 - 0.1500
52-Week Range	0.6000 - 6.9500
Beta	2.15
RSI	51.57
Earnings Date	May 9, 2025

About Bio Vitos Pharma AB

Bio Vitos Pharma AB (publ) operates as a medical technology company in Sweden and internationally. The company develops and commercializes Helge, which detects hemolysis in vacuum tubes and blood gas samples. It serves emergency departments in the European Union and the United States. It has a collaboration agreement with KFUM Kalmar to conduct a research study. The company was formerly known as Hemcheck Sweden AB (publ) and changed its name to Bio Vitos Pharma AB (publ) in December 2023. Bio Vitos Pharma AB (publ) was incorporated in 2010 and ...

• Industry: Surgical and Medical Instruments and Apparatus
• Founded: 2010
• Employees: 1
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: BIOVIT

Financial Performance

In 2024, Bio Vitos Pharma AB's revenue was 410,627, a decrease of -86.29% compared to the previous year's 3.00 million. Losses were -19.86 million, 54.4% more than in 2023.